← Leaderboards
Shannon Kelley
University Of Virginia
$106,750
Attributed
$106,750
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $36.5K · FY2021–23$50K$37.5K$25K$12.5K$0
'21
'22
'23
Funding mix
By agency
NIH$106,750 · 1
By mechanism
F31$106,750 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Golam Mohi$10,072,497
- Avril V. Somlyo$10,788,474
- William A Petri$62,342,757
- Zygmunt S Derewenda$13,312,270
- Urszula Derewenda$920,033
Others in their field
Other Emerging Leaders on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Jacob Ruff · Cornell University$22,500,000
- Elke Arenholz · Cornell University$14,750,000
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$14,335,772
- Amitinder Kaur · Tulane University Of Louisiana$12,771,713
Research focus
EnzymesCytoplasmic TailEmbryoApoptoticCytoplasmic ProteinApolipoprotein EAtherosclerosisAffectBiochemicalBloodAreaCause Of DeathCell DeathArterial Fatty StreakCell LineCell MembraneApoptosisCellsCerebrovascular DisordersChimeric ProteinsCholesterolCytokineCardiovascular DiseasesEpithelial Cells
Grant awards (4)
Testing the tyrosine phosphatase SHP-2 as a novel brake on efferocytosis$36,450
F31 · FY2023 · HL · contact PI
Testing the tyrosine phosphatase SHP-2 as a novel brake on efferocytosis$35,508
F31 · FY2022 · HL · contact PI
Testing the tyrosine phosphatase SHP-2 as a novel brake on efferocytosis$23,673
F31 · FY2021 · HL · contact PI
Testing the tyrosine phosphatase SHP-2 as a novel brake on efferocytosis$11,119
F31 · FY2021 · HL · contact PI